PSB-12379-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEPSB-12379Cat.No.:HY-100747CASNo.:1802226-78-3分?式:C??H??N?O?P?分?量:529.38作?靶點:CD73作?通路:Immunology/Inflammation儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗H2O:125mg/mL(236.13mM;Needultrasonic)DMSO:≥5mg/mL(9.45mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.8890mL9.4450mL18.8900mL5mM0.3778mL1.8890mL3.7780mL10mM0.1889mL0.9445mL1.8890mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。體內實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：PBSSolubility:100mg/mL(188.90mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性PSB-12379?種核苷酸類似物，?種有效的Ecto-5'-Nucleotidase(CD73)抑制劑，Kis值為9.03nM(?)和2.21nM(?)。IC50&TargetKi:9.03nM(rat),2.21nM(human)(Ecto-5’-Nucleotidase)[1]體外研究Metabolism:Onlyasmallpercentage(77%ofthecompoundsarerecoveredunchangedafteralongincubationfor8h.PSB-12379(10g)issomewhatlessstable,and56%aremetabolizedwithin8h.Hydrolyticcleavageoftheglycosidicbond,whichisatypicalphaseIreactionofnucleosidesandnucleotides,wasobservedasthemainreaction[1].戶使?本產(chǎn)品發(fā)表的科研?獻?FrontBioengBiotechnol.2022Apr27;10:895998.?Cancers(Basel).2022,14(23),5750Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].BhattaraiS,etal.α,β-Methylene-ADP(AOPCP)DerivativesandAnalogues:DevelopmentofPotentandSelectiveecto-5'-Nucleotidase(CD73)Inhibitors.JMedChem.2015Aug13;58(15):6248-63.[2].X-RayCo-CrystalStructureGuidestheWaytoSubnanomolarCompetitiveEcto-5-Nucleotidase(CD73)InhibitorsforCancerImmunotherapySanjayBhattarai.Adv.Therap.2019,2,1900075.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.T